SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies receives first patent for a novel antibiotic product

22 May 2012 Evaluate

Venus Remedies has received its first patent for a novel antibiotic combination of carbapenem and amino glycoside from Companies and Intellectual Property Registration Office (CIPRO), South Africa. Pioneering into antibacterial portfolio, Venus has added another international patent to its basket for the antibiotic combination rationally designed to result in a pharmaceutical low dose. Overall, Venus is enjoying a total tally of more than 80 patents for its innovative research products across the globe.

Venus Medicine Research Centre (VMRC) is constantly working on innovating new technologies and drugs for eradicating the most fatal disease in the world. The company has made amazing progress to treat serious fatal mixed multi-bacterial infectious diseases through their novel antibiotic combination of carbapenem and aminoglycoside. Having received this patent grant from CIPRO, South Africa, the company is hopeful of capturing a major share in the market.

Novel antibiotic combination is suitable for the treatment of bacterial/ multi-bacterial infections, and is particularly suitable for catering to the needs of all age groups ranging from the neonates, children, immune compromised patients, and the ones prone to serious fatal mixed multi-bacterial infectious disease.

Venus Remedies Share Price

948.70 -49.90 (-5.00%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×